The short version of research chemical fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-06. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Although most of its ecological habitats are still intact, there is an increasing population with industrial and tourism development. This is putting more pressure on the vegetation through the process of logging, overgrazing, woodcutting and infrastructure of development plans. Though the tree is widespread, it has become fragmented with the development that has occurred in its habitats. Many of its populations are suffering poor regeneration. Human activities have greatly reduced the population through overgrazing, and feeding the flowers and fruits to the livestock of the island. One of the greatest threats is the gradual drying out of the Socotra Archipelago, which has been an ongoing process for the last few hundred years. This has resulted in non-flourishing trees, and the duration of the mist and cloud around the area seems to also be decreasing. Increasingly arid environments are predicted to cause a 45 percent reduction in the available habitat for D. cinnabari by 2080. Another threat comes from goat grazing in the area, which prevents regeneration and prevents seedlings developing in locations other than rocky outcrops. Additional threats include harvesting of its resin and use of its leaves as fodder during the dry season. Presently some trees have been used to make beehives. This was generally prohibited; this displays how the species may be threatened by a breakdown in the traditional practices of the island. The best preserved and largest stand of D. cinnabari is on the limestone plateau named Rokeb di Firmihin.
=== Nutritional aspects === The bioavailability of protein from raw eggs (51%) is significantly lower than from cooked eggs (91%). Additionally, raw egg whites contain avidin, which inhibits the absorption of biotin. Consuming large amounts of raw egg white over long periods can potentially lead to biotin deficiency. Conversely, some research suggests egg white protein may help lower high cholesterol levels.
Gypsum plasters Cementitious plasters Fibrous plasters Gypsum plasters may include chemical additives that create bubbles by releasing carbon dioxide, thus reducing the bulk density. Lightweight, shredded polystyrene beads may be pre-mixed into the plaster to reduce its density. Mineral plasters can be classified in the non-combustible building material classes of the European standard EN 13501-1, A1 (no combustible components) and A2 (with combustible components), with supplementary ratings for smoke production (s1–s3) and dripping (d0–d2); for example, Knauf's lime-based spray plaster Raumklima Spritzputz is rated A1, and its lime-based trowel plaster Raumklima Scheibenputz is rated A2-s1, d0. Fibrous plasters contain a matrix of mineral wool or cellulosic fibres; the large amount of air entrained between the fibres is difficult to transfer heat through, giving the low-density material higher thermal efficiency per unit thickness. Proprietary boards and sheets made of gypsum, calcium silicate, or vermiculite, and mechanically-bonded composite boards made of punched sheet metal and fibre-reinforced cement have all been used to protect structural steel and other building elements for increased fire resistance. An alternative method to keep building steel temperature below the critical strength limit is to use liquid convection cooling in hollow structural members. This method was patented in the 19th century although the first prominent example was 89 years later.
Calorie restriction to promote weight loss is generally recommended. Around 80 percent of obese people with type 2 diabetes achieve complete remission with no need for medication if they sustain a weight loss of at least 15 kilograms (33 lb), but most patients are not able to achieve or sustain significant weight loss. Even modest weight loss can produce significant improvements in glycemic control and reduce the need for medication. Several diets may be effective such as the DASH diet, Mediterranean diet, low-fat diet, or monitored carbohydrate diets such as a low carbohydrate diet. Other recommendations include emphasizing intake of fruits, vegetables, reduced saturated fat and low-fat dairy products, and with a macronutrient intake tailored to the individual, to distribute calories and carbohydrates throughout the day. A 2021 review showed that consumption of tree nuts (walnuts, almonds, and hazelnuts) reduced fasting blood glucose in diabetic people. As of 2015, there is insufficient data to recommend nonnutritive sweeteners, which may help reduce caloric intake. An elevated intake of microbiota-accessible carbohydrates can help to reduce the effects of T2D. Viscous fiber supplements may be useful in those with diabetes. Culturally appropriate education may help people with type 2 diabetes control their blood sugar levels for up to 24 months. There is not enough evidence to determine if lifestyle interventions affect mortality in those who already have type 2 diabetes.
Sources: en.wikipedia.org
=== Affinity selection-mass spectrometry === While adoption of affinity selection-mass spectrometry (AS-MS) has led to an expansion of assay formats, the general technique follows a simple scheme. Protein targets are incubated with small molecules to allow for the formation of stable ligand-protein complexes, unbound small molecules are removed from the mixture, and the components of remaining ligand-protein complexes are analyzed using mass spectrometry. The bound ligands identified are then categorized as hits and can be used to provide a starting point for lead generation. Since AS-MS measures binding in an unbiased manner, a hit does not need to be tied to a functional readout, opening the possibility of identifying drugs that act beyond active sites, such as allosteric modulators and chemical chaperones, all in a single assay. Because small molecules can be directly identified by their exact mass, no derivatization is needed to confirm the validity of a hit. Among derivatization- and label-free approaches, AS-MS has the unique advantage of being amenable to the assessment of multiple test compounds per experiment—as many as 20,000 compounds per experiment have been reported in the literature, and one group has reported assaying chemical libraries against heterogeneous protein pools. The basic steps of AS-MS are described in more detail below.
=== Familial (ATTRm-CM) === This type is caused by mutations of genes encoding amino acids of the transthyretin protein (TTR) causing transthyretin misfolding. Due to the multiple number of potential genetic causes (approximately 130 gene variants are known) the incidence of this form is variable in different populations, depending on the genetic variant. The vast majority of familial cardiac amyloidosis still present after the age of 60. A common mutation is the TTR gene mutation Val122Ile. It is estimated that 3.5–4% of African Americans in the United States have the Val 122lle mutation. This type of amyloidosis can be identified by genetic testing for protein mutation. Histological evaluation involves special stains being utilized to visualize the amyloid deposits. One such stain is Congo Red, which binds specifically to the amyloid deposits and can be characterized by various lighting methods. Under polarized light, the amyloid deposits show characteristic apple green birefringence, and under plain light the deposits will appear a light salmon pink color. Familial amyloidosis usually causes a combination of heart failure and peripheral neuropathy or autonomic neuropathy. Whereas wild-type transthyretin amyloidosis usually causes heart failure, with neuropathy being more rare.
== Veterinary use == The veterinary use of chlorpromazine has generally been superseded by the use of acepromazine. Chlorpromazine may be used as an antiemetic in dogs and cats, or, less often, as a sedative before anesthesia. In horses, it often causes ataxia and lethargy and is therefore seldom used. It is commonly used to decrease nausea in animals that are too young for other common antiemetics. It is sometimes used as a preanesthetic and muscle relaxant in cattle, swine, sheep, and goats. The use of chlorpromazine in food-producing animals is not permitted in the European Union, as a maximum residue limit could not be determined following assessment by the European Medicines Agency.
Sources: en.wikipedia.org
He had to choose a college, and he chose to study at Magdalen College, Oxford, where his high school headmaster, Henry Girdlestone, had gone. He enrolled in the honour school of physiology, where he studied under the tutelage of Sir Charles Scott Sherrington. During the summer breaks he visited France, Belgium, Germany, Italy, Czechoslovakia and Austria. He became a demonstrator in the physiology department, and he applied for a fellowship in physiology at Merton College, but was passed over in favour of Gavin de Beer. He was awarded the degree of Bachelor of Arts in 1924. At Sherrington's instigation, he studied the cerebral cortex of cats. A paper was published in Brain in March 1925. His thesis on "The capillary circulation together with associated observations made in connexion with this investigation" was later examined by John Scott Haldane and John Gillies Priestley on 2 May 1925, and he was awarded a Bachelor of Science degree. Florey was elected to a John Lucas Walker Studentship at the University of Cambridge for the 1924–1925 academic year. This came with a stipend of £300 plus £200 for equipment. Before taking up this new position, he participated in the 1924 Oxford University Arctic Expedition as the medical officer. In July 1925, he won a fellowship from the Rockefeller Foundation to study in the United States.
Isotope masses from: Audi, Georges; Bersillon, Olivier; Blachot, Jean; Wapstra, Aaldert Hendrik (2003), "The NUBASE evaluation of nuclear and decay properties", Nuclear Physics A, 729: 3–128, Bibcode:2003NuPhA.729....3A, doi:10.1016/j.nuclphysa.2003.11.001 Isotopic compositions and standard atomic masses from: de Laeter, John Robert; Böhlke, John Karl; De Bièvre, Paul; Hidaka, Hiroshi; Peiser, H. Steffen; Rosman, Kevin J. R.; Taylor, Philip D. P. (2003). "Atomic weights of the elements. Review 2000 (IUPAC Technical Report)". Pure and Applied Chemistry. 75 (6): 683–800. doi:10.1351/pac200375060683. Wieser, Michael E. (2006). "Atomic weights of the elements 2005 (IUPAC Technical Report)". Pure and Applied Chemistry. 78 (11): 2051–2066. doi:10.1351/pac200678112051. "News & Notices: Standard Atomic Weights Revised". International Union of Pure and Applied Chemistry. 19 October 2005. Half-life, spin, and isomer data selected from the following sources. Audi, Georges; Bersillon, Olivier; Blachot, Jean; Wapstra, Aaldert Hendrik (2003), "The NUBASE evaluation of nuclear and decay properties", Nuclear Physics A, 729: 3–128, Bibcode:2003NuPhA.729....3A, doi:10.1016/j.nuclphysa.2003.11.001 Holden, Norman E. (2004). "11. Table of the Isotopes". In Lide, David R. (ed.). CRC Handbook of Chemistry and Physics (85th ed.). Boca Raton, Florida: CRC Press. ISBN 978-0-8493-0485-9. National Nuclear Data Center. "NuDat 3.0 database". Brookhaven National Laboratory.
Peters has played audio of the racial slur nigger. He has also been known to wear a hat bearing the word and Bernstein described his use of it as "chronic". Helen Rummel of The Arizona Republic wrote that he was "well-known" for "the use of racist slurs in his livestreams". Peters said on a livestream that "It's not a racist thing. It's just a fun word to say." The Atlantic's Charlie Warzel wrote that he "revel[s] in anti-Semitism". Peters stated, "I'm more of, like, a moggist, not a racist." In February 2026, a tweet describing Peters as having been "brutally frame mogged" by an Arizona State University fraternity leader in a video became a copypasta and meme. The term jestermaxxing, used to describe having fun, also spread online that month due to its use in video captions of Peters dancing at the club. The suffixes -mogging and -maxxing and the incel term foid, a shortening of the portmanteau femoid, which describes women as subhuman, found popular usage online by February 2026 due to these and other memes of Peters. They were typically posted by "clippers", social media users who repost clips from livestreams with eye-catching captions and, according to Katie Notopoulos of Business Insider, often "have a financial motive" to be paid by creator programs or influencers. Bernstein also noted that some Kick users were paid by the platform for clipping Peters's livestreams.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.